Filipcsei, Genoveva,Otvos, Zsolt,Pongracz, Katalin,Darvas, Ferenc
申请号：
AU2010261511
公开号：
AU2010261511A1
申请日:
2010.06.18
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc.
